Effects of OP 2507, a stable analogue of prostaglandin I2, on carbon tetrachloride-induced liver damage in starved rats.
It has been reported that vasodilatory prostaglandins have cytoprotective effects against various types of liver damage. We investigated the effects OP 2507, a stable analogue of prostaglandin I2, on carbon tetrachloride-induced liver damage in starved rats. Intraperitoneal administration of OP 2507 at 1,500 micrograms/kg lessened both an increase in serum alanine aminotransferase activity and an inhibition of starvation ketosis, both of which were induced by carbon tetrachloride. At lower doses, however, OP 2507 not only failed to ameliorate the carbon tetrachloride-induced changes, but it actually exaggerated them. Although the deterioration of carbon tetrachloride-induced liver damage by lower doses of OP 2507 was not statistically significant, it seems possible that OP 2507 has dual effects on carbon tetrachloride-induced liver damage. While none of the three agents cimetidine, reduced glutathione and deferoxamine, prevented increase in serum alanine aminotransferase activity induced with lower dose OP 2507, allopurinol had a tendency to prevent the increase, indicating that lower doses of OP 2507 may promote a reaction catalyzed by xanthine oxidase. We propose that both the co-administration of prostaglandins and other potentially hepatotoxic drugs, and the administration of prostaglandins to patients with drug-induced liver damage should be done carefully.
Irita
K
K
Department of Anesthesiology and Critical Care Medicine, Kyushu University School of Medicine, Fukuoka, Japan.
Sakai
H
H
Yamakawa
M
M
Nawata
H
H
Yoshitake
J
J
Takahashi
S
S
D000410:Alanine Transaminase / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D002252:Carbon Tetrachloride Poisoning / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D056486:Chemical and Drug Induced Liver Injury / Q000378:metabolism / Q000473:pathology*; D002927:Cimetidine / Q000494:pharmacology; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D007657:Ketone Bodies / Q000378:metabolism; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013217:Starvation / Q000473:pathology*
D000975:Antioxidants; D006635:Histamine H2 Antagonists; D007657:Ketone Bodies; C049453:OP 2507; D002927:Cimetidine; D011464:Epoprostenol; D000410:Alanine Transaminase